Clearside Biomedical Inc
NASDAQ:CLSD 2:33:31 PM EDT
Products, Regulatory, Earnings Announcements
Clearside Biomedical Announces 6-Month Results From Oasis Extension Study
Published: 02/02/2023 13:27 GMT
Clearside Biomedical Inc (CLSD) - Clearside Biomedical Announces Positive 6-month Results From Oasis Extension Study With Suprachoroidal Cls-ax in Wet Amd.
Clearside Biomedical Inc - 67% of Extension Study Participants Went at Least 6 Months Without Needing Additional Treatment.
Clearside Biomedical Inc - Extension Participants Experienced a 77 - 85% Reduction in Treatment Burden Over 6 Months.
Clearside Biomedical- Expect to Initiate Randomized, Controlled, Double-masked, Phase 2b Clinical Trial, Called Odyssey, in Q1 This Year.
Clearside Biomedical Inc - Primary Endpoint Readout Anticipated in Mid-2024.
Clearside Biomedical Inc - 67% of Extension Study Participants Went at Least 6 Months Without Needing Additional Treatment.
Clearside Biomedical Inc - Extension Participants Experienced a 77 - 85% Reduction in Treatment Burden Over 6 Months.
Clearside Biomedical- Expect to Initiate Randomized, Controlled, Double-masked, Phase 2b Clinical Trial, Called Odyssey, in Q1 This Year.
Clearside Biomedical Inc - Primary Endpoint Readout Anticipated in Mid-2024.
Revenue is expected to be $0.15 Million
Adjusted EPS is expected to be -$0.14
Next Quarter Revenue Guidance is expected to be $0.15 Million
Next Quarter EPS Guidance is expected to be -$0.14
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.14
Next Quarter Revenue Guidance is expected to be $0.15 Million
Next Quarter EPS Guidance is expected to be -$0.14
More details on our Analysts Page.